529508-58-5

Basic information

• Product Name: 1-[(3-Fluorophenyl)methyl]-5-nitro-1H-indazole
• Synonyms: 1-[(3-Fluorophenyl)methyl]-5-nitro-1H-indazole;1H-Indazole, 1-[(3-fluorophenyl)methyl]-5-nitro-;1-(3-Fluorobenzyl)-5-nitro-1H-indazole
• CAS NO: 529508-58-5
• Molecular Formula: C₁₄H₁₀FN₃O₂
• Molecular Weight: 271.25
• Product Categories: API intermediates
• Mol File: 529508-58-5.mol

Chemical Properties

• Boiling Point: 447.697°C at 760 mmHg
• Flash Point: 224.559°C
• Appearance: /
• Density: 1.382g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.654
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: -0.82±0.30(Predicted)
• CAS DataBase Reference: 1-[(3-Fluorophenyl)methyl]-5-nitro-1H-indazole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[(3-Fluorophenyl)methyl]-5-nitro-1H-indazole(529508-58-5)
• EPA Substance Registry System: 1-[(3-Fluorophenyl)methyl]-5-nitro-1H-indazole(529508-58-5)

Safety Data

• Hazardous Substances Data: 529508-58-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
1-[(3-Fluorophenyl)methyl]-5-nitro-1H-indazole is used as a research compound for exploring its potential bioactivity and pharmacological properties. Its unique structure suggests that it may contribute to the development of new drugs, especially in the fields of antifungal or antimicrobial agents.
Used in Drug Development:
In the pharmaceutical industry, 1-[(3-Fluorophenyl)methyl]-5-nitro-1H-indazole is utilized as a starting material or a building block in the synthesis of novel drug candidates. Its chemical properties and structural features can be further modified to enhance its therapeutic potential and target specific biological pathways.
Further research and testing are required to fully understand the compound's potential applications and effects in pharmaceutical or biomedical settings, ensuring its safety and efficacy for future therapeutic use.

InChI:InChI=1/C14H10FN3O2/c15-12-3-1-2-10(6-12)9-17-14-5-4-13(18(19)20)7-11(14)8-16-17/h1-8H,9H2

Upstream product

• 456-41-7 1-(Bromomethyl)-3-fluorobenzene 
• 456-42-8 m-fluorobenzyl chloride 
• 5401-94-5 5-nitroindazole 

Downstream Products

• 856667-80-6 4-(1-(3-fluorobenzyl)-1H-indazol-5-ylamino)-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxylic acid 
• 856667-79-3 ethyl 4-[1-(3-fluoro-benzyl)-1H-indazol-5-ylamino]-5-methyl-pyrrolo[2,1-f][1,2,4]triazine-6-carboxylate 
• 914308-85-3 {5-cyano-6-[1-(3-fluoro-benzyl)-1H-indazol-5-ylamino]-pyrimidin-4-ylsulfanyl}-acetic acidethyl ester 
• 914308-84-2 4-chloro-6-[1-(3-fluoro-benzyl)-1H-indazol-5-ylamino]-pyrimidine-5-carbonitrile 
• 1353644-68-4 (3aR,6aR)-N-(4-(1-(3-fluorobenzyl)-1H-indazol-5-ylamino)-7-methoxyquinazolin-6-yl)-1-methylhexahydropyrrolo[3 ,4-b]pyrrole-5(1 H)-carboxamide 
• 1353644-76-4 C₃₀H₂₃FN₆O₃ 
• 897025-61-5 N⁴-(1-(3-fluorobenzyl)-1H-indazol-5-yl)-7-methoxyquinazoline-4,6-diamine 
• 1353644-75-3 N-(1-(3-fluorobenzyl)-1H-indazol-5-yl)-7-methoxy-6-nitroquinazolin-4-amine 
• 1338250-46-6 C₂₉H₂₆FN₇ 
• 1338250-42-2 C₃₀H₂₆FN₇ 
• 1338250-38-6 C₂₉H₂₄FN₇O 

Relevant articles and documents

Hetero-aromatic compound and its use in medicine

The invention provides a hetero-aromatic compound or a stereisomer, geometric isomer, tautomer, despinner, nitrogen oxide, hydrate, solvate, metabolite, metabolism precursor and pharmaceutically acceptable salt or prodrug thereof, which is used for treating proliferative diseases. The invention also discloses a pharmaceutical composition containing the compound and an application of the compound or pharmaceutical composition thereof in preparation of a medicine for treating proliferative diseases.

QUINAZOLINE COMPOUNDS

Provided are certain quinazoline compounds, compositions thereof and methods of use thereof. These quinazoline compound can effectively inhibit the overexpression and/or overactivity of epidermal growth factor receptor (EGFR).

QUINAZOLINE COMPOUNDS

Provided are certain quinazoline compounds, compositions thereof and methods of use thereof. These quinazoline compounds can effectively inhibit the overexpression and/or overactivity of epidermal growth factor receptor (EGFR).

Synthesis and cytotoxic activity of 2,5-disubstituted pyrimido[5,4-c] quinoline derivatives

A series of 2,5-disubstituted pyrimido[5,4-c]quinoline derivatives were synthesized and their cytotoxic activity against H460, HT-29 and MDA-MB-231 cell lines was evaluated in vitro. It was found that most of the tested compounds especially compound 17, s

PHOSPHORUS CONTAINING QUINAZOLINE COMPOUNDS AND METHODS OF USE

Disclosed are novel quinazoline derivatives containing phosphorus substitutions and methods for the treatment of hyperproliferative diseases (e.g. cancer) using the compounds. These compounds are type I receptor protein kinase inhibitors useful in treating disorders related to abnormal protein kinase activities such as cancer and inflammation in mammals. Also disclosed are pharmaceutical compositions containing the compounds, methods for the preparation of the compounds and their pharmaceutically acceptable salts.

Synthesis and evaluation of aniline headgroups for alkynyl thienopyrimidine dual EGFR/ErbB-2 kinase inhibitors

Aniline 'headgroups' were synthesized and incorporated into an alkynyl thienopyrimidine series of EGFR and ErbB-2 inhibitors. Potent inhibition of enzyme activity and cellular proliferation was observed. In certain instances, protein binding was reduced a

Discovery and preclinical evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H- indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic acid, (3S)-3-morpholinylmethyl ester (BMS-599626), a selective and orally efficacious inhibitor of human epide

Structure-activity relationships in a series of 4-[1H-indazol-5-ylamino] pyrrolo[2,1-f][1,2,4]triazine-6-carbamates identified dual human epidermal growth factor receptor (HER)1/HER2 kinase inhibitors with excellent biochemical potency and kinase selectiv

4- (IH-INDAZOL-S-YL-AMINO)-QUINAZOLINE COMPOUNDS AS ERBB RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER

A quinazoline derivative of the Formula I: wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm blood

NOVEL HETEROCYCLES

The invention relates to novel heterocycles of formula (I) processes for their preparation and their use for preparing medicaments for the treatment or prophylaxis of disorders, especially of hyperproliferative disorders.

THIA-TETRAAZAACENAPHTHYLENE KINASE INHIBITORS

The present invention is directed to novel thia-tetraazaacenaphthylene compounds of Formula (I): and pharmaceutically acceptable forms thereof and their synthesis and use as inhibitors of ATP-protein kinase interactions.